Effect of tofacitinib on cardiovascular events and all-cause mortality in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials.

There was a trend toward increased cardiovascular risk in 5 mg tofacitinib twice daily (all CVEs: OR 1.96, 95% CI 0.80–4.79; MACEs: OR 3.38, 95% CI 0.92–12.41) and a trend toward decreased cardiovascular risk (all CVEs: OR 0.48, 95% CI 0.16–1.44; MACEs: OR 0.97, 95% CI 0.15–6.27) in 10 mg tofacitinib twice daily in comparison to placebo in a short-term perspective, but the differences did not reach statistical significance ( Supplementary Figures S1–S4 ).

also in 111,027 other papers